Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450638 | 0.91 | CA9 (0.43) | CA9CA1CA2GPBAR1LMNA | |
| SCHEMBL14399285 | 0.86 | LMNA (0.54) | CA9CA1CA2GPBAR1LMNA | |
| SCHEMBL14400884 | 0.86 | LMNA (0.54) | CA9CA1CA2GPBAR1LMNA | |
| SCHEMBL5443587 | 0.82 | CA9 (0.40) | CA9CA1CA2GPBAR1LMNA | |
| SCHEMBL14399188 | 0.82 | CA9 (0.40) | CA9CA1CA2GPBAR1LMNA | |
| SCHEMBL5442215 | 0.81 | GPBAR1 (0.64) | GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL13351911 | 0.81 | GPBAR1 (0.64) | GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL14398790 | 0.81 | GPBAR1 (0.64) | GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL3525117 | 0.81 | GPBAR1 (0.64) | GPBAR1LMNANT5ESMN1; SMN2 | |
| SCHEMBL10081999 | 0.81 | PTPN1 (0.52) | GPBAR1LMNANT5ESMN1; SMN2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | ADVANCED LIFE SCIENCES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232577-A1 | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | BET1, PGGT1B, BRCA1 | CA9 779/4885CA1 193/4885CA2 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.